Yes, BCBS Federal does cover Zepbound for weight loss in 2026, but coverage is conditional: Zepbound is not on the standard FEP formulary, so your prescriber has to request a formulary exception, you have to clear prior authorization criteria, and even once approved the drug sits on a higher cost-sharing tier under most plan options.
What It Takes to Get Zepbound Approved
Two things have to happen before an FEP member can fill a Zepbound prescription through the plan. First, because Zepbound is not on the formulary, a healthcare provider must submit a formulary exception request on the member’s behalf. Members cannot file this themselves. Second, the prescription has to meet prior authorization criteria under FEP policy 5.99.031, approved by the FEP Pharmacy and Medical Policy Committee on December 12, 2025 and effective January 1, 2026.
Providers can download the FEP Traditional Formulary Exception Form (for traditional FEHB and PSHB members) or the FEP MPDP Formulary Exception Form (for members in the Medicare Prescription Drug Program) from the FEP pharmacy FAQ page. Requests can also be phoned in: 1-877-727-3784 for traditional plans, 1-855-344-0930 for MPDP.
Clinical Criteria You Have to Meet
To qualify for an initial six-month authorization, you must be at least 18 and meet all of the following:
- A BMI of 30 or higher, or a BMI of 27 or higher with either established cardiovascular disease or at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol.
- A documented history of trying at least two oral weight loss medications (for example, phentermine, Qsymia, diethylpropion, or benzphetamine) with an inadequate response, intolerance, or contraindication.
- A prior trial of the plan’s preferred GLP-1 product, unless there is a documented adverse reaction or contraindication. FEP’s preferred GLP-1 for weight loss is Wegovy.
- Active participation in a comprehensive weight management program.
- No concurrent use of another GLP-1 (such as Ozempic or Wegovy) or another weight loss drug that requires prior authorization (such as Contrave or Qsymia).
The initial approval covers 12 single-dose pens per 84 days for six months. If you don’t show an appropriate drop in BMI after 12 to 16 weeks, the policy calls for discontinuation.
What You’ll Pay Once Zepbound Is Approved
Tier placement, and therefore cost, depends on which FEP option you carry. For 2026, an approved Zepbound prescription lands as follows:
- FEP Blue Focus: Tier 2 (Preferred), 40% coinsurance up to $500 for a 30-day supply.
- FEP Blue Basic: Tier 3 (Non-Preferred), 60% coinsurance at retail pharmacies.
- FEP Blue Standard: Tier 3 (Non-Preferred), 50% coinsurance at retail, or 20% coinsurance through mail-order with a $250 per-prescription maximum.
One important limit: FEP does not allow a tier exception for Zepbound. Even with an approved formulary exception, your cost-sharing stays at the tier the drug is assigned.
Keeping Coverage After the First Six Months
Renewal is not automatic. To continue Zepbound past the initial authorization, you have to show either documented weight loss of at least 5% of your baseline body weight or maintenance of a previous 5% loss, and you have to still be participating in a weight management program. Renewed authorizations run 12 months.
If Your Request Is Denied
A denied formulary exception comes with a letter to both the member and the provider explaining appeal rights. The first step is an internal appeal: write to the local Blue Cross Blue Shield plan that processed the claim within six months of the initial decision. Explain why the denial was incorrect, cite the specific benefit provisions, and attach supporting documents such as physician letters, medical records, and explanation of benefits forms.
The plan must route the appeal to a healthcare professional who was not involved in the original decision. For post-service claims, the plan has 30 days to reverse the decision or issue a written response upholding it. You can also ask your provider to call the plan’s medical director for a peer-to-peer review of the clinical rationale.
If the internal appeal fails, you can escalate to the U.S. Office of Personnel Management. A binding external independent review is typically available within about 120 days of an internal denial, at no cost to the member.
The Weight Management Program Requirement
Because the policy conditions approval on participation in a comprehensive weight management program, this is a step worth starting early. FEP offers the Teladoc Health weight management program at no out-of-pocket cost. It includes a personalized plan with live coaching, nutrition and exercise guidance, a smart digital scale that syncs to the Teladoc app, stress and sleep management support, and food tracking with dietitian feedback.
Eligibility runs to members 13 or older with a pharmacy or medical claim in the past three years showing an adult BMI of 25 or higher (or a pediatric claim at the 85th percentile or higher). You enroll through your MyBlue account at fepblue.org/myblue. A diabetes diagnosis is not required. Other programs can satisfy the requirement too, as long as they combine behavioral modification, a reduced-calorie diet, and increased physical activity.
Manufacturer Savings Cards Don’t Apply
Eli Lilly runs savings card programs for Zepbound, but federal employees enrolled in BCBS FEP cannot use them. The program terms exclude anyone enrolled in any state, federal, or government-funded healthcare program, and FEP falls within that exclusion. The only route to lower costs for FEP members is the plan’s own formulary and tier structure.
A Separate Option for Federal Retirees on Medicare
Retirees enrolled in Medicare Part D through an FEHB carrier get an additional path starting July 1, 2026. The Centers for Medicare and Medicaid Services is launching the Medicare GLP-1 Bridge Program, a demonstration that provides certain GLP-1 weight loss drugs at a flat $50 copay per prescription. The program covers all formulations of Wegovy and Foundayo, plus the KwikPen formulation of Zepbound.
The prior authorization is submitted by the provider to a CMS central processor rather than to the FEHB plan, and the attestation requires that the beneficiary be at least 18 with a BMI of 35 or higher (or 30 with underlying medical conditions, or 25 in some cases). The demonstration is set to end December 31, 2027. One caveat worth planning around: the $50 copay does not count toward Part D catastrophic limits or an FEHB plan’s medical catastrophic limit, so total annual out-of-pocket spending can rise even as the per-fill price drops.